Prognostic and clinicopathologic significance of MicroRNA-125a-5p in cancers
A meta-analysis

Haidong Ye, MM\textsuperscript{a}, Wei Zhu, BS\textsuperscript{b}, Lina Mei, MM\textsuperscript{c}, Zhouxiang Lu, MM\textsuperscript{d,*}

Abstract

The aim of the study was to estimate the prognostic and clinicopathologic significance of miR-125a-5p in human cancers. Eligible studies were obtained from PubMed, Embase, and the Cochrane Library. Combined hazard ratios (HRs) and odds ratios (ORs) were used to evaluate the prognostic and clinicopathologic value of miR-125a-5p. In pan-cancer, high miR-125a-5p expression was associated with better overall survival (OS) (HR = 0.459, 95% confidence interval [CI]: 0.369–0.57, P < .001), and disease-free survival (HR = 0.343, 95% CI: 0.237–0.496, P < .001). Furthermore, favorable OS was also found in lung cancer (HR = 0.343, 95% CI: 0.228–0.517, P < .001) and gastric cancer (HR = 0.341, 95% CI: 0.160–0.725, P = .005) patients with high miR-125a-5p expression. Besides, high miR-125a-5p expression was correlated with early stage (OR = 0.413, 95% CI: 0.228–0.749, P = .004) and negative lymph node metastasis (OR = 0.262, 95% CI: 0.073–0.941, P = .04) in gastric cancer, and was linked with better tumor differentiation in pan-cancer (OR = 1.623, 95% CI: 1.064–2.476, P = .025) and lung cancer (OR = 2.371, 95% CI: 1.368–4.141, P = .002). In conclusion, miR-125a-5p is a tumor suppressor with prognostic and clinicopathologic values for human cancer, and miR-125a-5p overexpression predicted favorable prognosis, early stage, negative lymph node metastasis, and better tumor differentiation. More research should be conducted to test these results.

Abbreviations: 95% CIs = 95% confidence intervals, DFS = disease-free survival, ESCC = esophageal squamous cell carcinoma, GIST = gastrointestinal stromal tumor, HCC = hepatocellular cancer, HRs = hazard ratios, miR-125a-5p = MicroRNA-125a-5p, OR = odds ratio, OS = overall survival, qRT-PCR = quantitative real-time PCR, SACC = salivary adenoid cystic carcinoma.

Keywords: cancer, clinicopathologic parameter, meta-analysis, MicroRNA-125a-5p, prognosis

1. Introduction

MicroRNAs (miRNAs) are small noncoding RNA molecules containing 19 to 25 nucleotides and regulate posttranscriptional gene expression by binding to their target mRNAs, usually in the 3’-untranslated region.[1] Numerous miRNAs are abnormally expressed in tumors and can function as tumor suppressors or oncogenes. They often have prognostic value regarding tumor development and clinicopathologic parameters.[2,3] miRNAs serve a vital role in various cellular processes, including cellular growth, differentiation, proliferation, metastasis, migration, and apoptosis.[4] The aberrant expression of MicroRNA-125a-5p (miR-125a-5p) located on 19q13.41, may function as tumor suppressors in various cancers, including gastric,[5,6] lung,[7] breast,[8] and gliomas.[9] The prognostic value and clinicopathologic significance of miR-125a-5p were inconsistent among previous studies. In the present study, we conducted a meta-analysis to estimate the prognostic and clinicopathologic significance of miR-125a-5p.

2. Methods

Our study was conducted following the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines. In addition, our meta-analysis was conducted by reviewing issued papers, thus, the ethical approval is not required.

2.1. Literature search

We performed a literature search in PubMed, Embase, and the Cochrane Library (last update by February 12, 2019), using the following keywords (miR-125a-5p OR microRNA-125a-5p OR microRNA-125a-5p OR miR125a-5p OR miRNA125a-5p OR mir125a-5p OR microRNA125a-5p OR “miR-125a-5p" OR “miRNA 125a-5p” OR "microRNA 125a-5p" OR mir125a-5p OR mir-125a-5p OR microRNA-125a-5p OR microRNA-125a-5p OR mir-125a-5p OR microRNA-125a-5p OR microRNA-125a-5p OR microRNA125a-5p OR microRNA125a-5p) AND (malignant OR cancer OR tumor OR tumour OR neoplas* OR carcinoma OR adenocarcinoma OR sarcoma). A manual review of the reference lists in relevant articles was also conducted.
2.2. Literature selection

Studies met the following inclusion criteria were included: study with any type of cancer; detection of miR-125a-5p expression in blood-based samples or primary tissue samples; survival and/or clinicopathologic parameters were investigated and miR-125a-5p expression were grouped into high expression or low expression; and raw data of clinicopathologic parameter was available, or the survival curve or sufficient relevant data were available to calculate hazard ratio (HR). The exclusion criteria were: miR-125a-5p was combined with other biomarker; no sufficient data; and duplicated publication.

2.3. Data extraction and quality assessment

The following details were collected from each included study: 1st author, publication year, country, cancer type, stage, sample source, test method, sample size, clinicopathologic parameters, follow-up time, survival index, statistical method, HR as well as 95% confidence interval (CI; extracted using the described method in previous studies[10,11]), the survival outcome of the high miR-125a-5p expression group and quality score of study. The quality of the study was evaluated by the Newcastle-Ottawa scale.[12]

2.4. Statistical analysis

Combined HRs and odds ratios (ORs) with corresponding 95% CIs were used to evaluate the prognostic and clinicopathologic value. HR < 1 with 95% CI not overlapping 1 was indicated a better survival for the case group (high expression of miR-125a-5p). Given that the various heterogeneities among individual HR, we calculated pooled HR by random-effect model as proposed in previous studies.[13] Heterogeneity among studies involved clinicopathologic parameters was estimated by the Q-statistic and I²-statistic. If significant heterogeneity (I² > 50%), the random-effect model was applied; if not, the fixed-effects mode. Publication bias was detected by Begg test. Analyses were carried out by the STATA 15.0 software (Stata Corporation, College Station, TX), and P < .05 indicates statistically significant.

3. Results

3.1. Literature research and characteristics

Totally 194 articles were retrieved from the initial search. As shown in Figure 1, 16 studies[2,3,5–9,14–22] with 2088 patients were included, from which 12 studies with 1803 patients involved prognosis and 12 studies with 1467 patients involved
Clinicopathologic features. The characteristics of enrolled studies were summarized in Tables 1 and 2. The included studies published from 2010 to 2018, and the sample sizes ranged from 30 to 384. Except the study of Akcakaya et al was conducted in Sweden, other studies were all carried out in Asia (China and Japan). Totally 10 kinds of cancers were included: lung cancer, gastric cancer, hepatocellular cancer, esophageal squamous cell carcinoma, gastrointestinal stromal tumor, breast cancer, glioma, retinoblastoma, salivary adenoid cystic carcinoma, and colorectal cancer, and only 3 OS studies based on serum sample, others based on tissue sample to investigate prognosis and clinicopathologic features. The expression level of miR-125a-5p was measured by quantitative real-time polymerase chain reaction (qRT-PCR) in all included studies. The survival index of overall survival (OS) was applied in all studies, but disease-free survival (DFS) was only enrolled in 2 studies. Multivariate analysis was used to estimate survival outcome in 7 studies, others applied Kaplan–Meier survival curve.

### 3.2. High miR-125a-5p expression predicted better prognosis

For OS, totally 1383 tissue samples and 490 serum samples were collected to detect the expression level of miR-125a-5p. Based on tissue sample, significant link was found between high miR-125a-5p expression and better OS (HR=0.459, 95% CI: 0.369–0.57, P < .001), but publication bias was also detected (P < .001).

### Table 1

| First author | Year | Country | Cancer type | Stage | Sample source | Test method | Sample size | Survival | Statistic method | HR | LL | UL | Outcome* | NOS |
|--------------|------|---------|-------------|-------|---------------|-------------|------------|----------|-----------------|----|----|----|----------|-----|
| Nishida et al | 2011 | Japan   | Gastric cancer | I–IV  | Tissue         | qRT-PCR     | 56         | OS        | Multivariate    | 0.376/0.358 | 0.237/0.240 | 0.584/0.521 | Better/NS | 7   |
| Zhang et al  | 2012 | China   | Lung cancer   | I–IV  | Tissue         | qRT-PCR     | 87         | OS        | Multivariate    | 0.410 | 0.149 | 0.966 | Better    | 6   |
| Zhu et al    | 2014 | China   | Lung cancer   | I–IV  | Tissue/Serum   | qRT-PCR     | 70         | OS        | Multivariate    | 0.134/1.291 | 0.028/0.444 | 0.643/3.758 | Better/NS | 7   |
| Hsieh et al  | 2015 | China   | Breast cancer | I–II  | Serum          | qRT-PCR     | 300        | OS        | Multivariate    | 0.421 | 0.184 | 0.961 | Better    | 6   |
| Zhang et al  | 2015 | China   | Lung cancer   | II    | Serum          | qRT-PCR     | 120        | OS        | Survival Curve  | 0.476 | 0.250 | 0.903 | Better    | 7   |
| Sun et al    | 2016 | China   | Glioma       | I–IV  | Tissue         | qRT-PCR     | 167        | OS        | Multivariate    | 0.560 | 0.390 | 0.810 | Better    | 7   |
| Liang et al  | 2017 | China   | SACC         | I–IV  | Serum          | qRT-PCR     | 106        | OS        | Survival Curve  | 0.561 | 0.270 | 0.937 | Better    | 7   |
| Sun et al    | 2016 | China   | Glioma       | II    | Serum          | qRT-PCR     | 167        | OS        | Multivariate    | 0.563 | 0.350 | 0.906 | Better    | 6   |
| Zhao et al   | 2018 | China   | ESCC         | I–IV  | Serum          | qRT-PCR     | 56         | OS        | Survival Curve  | 0.460 | 0.230 | 0.960 | Better    | 6   |
| Cao et al    | 2018 | China   | Gastric cancer | I–IV  | Serum          | qRT-PCR     | 82         | OS        | Survival Curve  | 0.52  | 0.27  | 0.99 | Better    | 7   |
| Cai et al    | 2018 | China   | Gastric cancer | I–IV  | Tissue         | qRT-PCR     | 286        | OS/DFS    | Multivariate    | 0.125/0.227 | 0.037/0.069 | 0.416/0.770 | Better/NS | 7   |
| Liu et al    | 2018 | China   | Lung cancer   | I–IV  | Tissue         | qRT-PCR     | 384        | OS/DFS    | Multivariate    | 0.376/0.358 | 0.237/0.240 | 0.584/0.521 | Better/NS | 7   |

DFS = disease-free survival, ESCC = esophageal squamous cell carcinoma, HCC = hepatocellular cancer, HR = hazard ratio, LL = lower limit, NOS = the scores of Newcastle–Ottawa quality assessment scale, NR = not report, OS = overall survival, qRT-PCR = quantitative real-time polymerase chain reaction, SACC = salivary adenoid cystic carcinoma, UL = upper limit.

* Outcome was for patient with high miR-125a-5p expression.

### Table 2

| First author | Year | Country | Cancer type | Sample source | Test method | Sample size | Clinicopathologic parameters | NOS |
|--------------|------|---------|-------------|---------------|-------------|------------|-------------------------------|-----|
| Jiang et al  | 2010 | China   | Lung cancer | Tissue         | qRT-PCR     | 52         | Gender, age, tumor differentiation, stage, and lymph node metastasis | 6   |
| Nishida et al| 2011 | Japan   | Gastric cancer | Tissue         | qRT-PCR     | 87         | Gender, age, tumor differentiation, stage, and lymph node metastasis | 6   |
| Zhu et al    | 2014 | China   | Lung cancer | Tissue         | qRT-PCR     | 70         | Gender, age, tumor differentiation, stage, and lymph node metastasis | 7   |
| Xu et al     | 2014 | China   | Gastric cancer | Tissue         | qRT-PCR     | 51         | Gender, age, tumor differentiation, stage, and lymph node metastasis | 7   |
| Akcakaya et al| 2014 | Sweden  | GIST        | Tissue         | qRT-PCR     | 30         | Distant metastasis             | 6   |
| Sun et al    | 2016 | China   | Glioma      | Tissue         | qRT-PCR     | 167        | Gender, age, and tumor differentiation | 7   |
| Zhang et al  | 2016 | China   | Retinoblastoma | Tissue        | qRT-PCR     | 112        | Gender, age, tumor differentiation, and stage | 7   |
| Liang et al  | 2017 | China   | SACC        | Tissue         | qRT-PCR     | 106        | Gender, age, tumor differentiation, stage, lymph node metastasis, and distant metastasis | 7   |
| Cao et al    | 2018 | China   | Gastric cancer | Tissue         | qRT-PCR     | 82         | Gender, age, tumor differentiation, stage, lymph node metastasis | 7   |
| Cai et al    | 2018 | China   | Gastric cancer | Tissue         | qRT-PCR     | 286        | Gender, age, tumor differentiation, and lymph node metastasis | 7   |
| Liu et al    | 2018 | China   | Lung cancer | Tissue         | qRT-PCR     | 384        | Gender, age, tumor differentiation, stage, lymph node metastasis, and distant metastasis | 7   |
| Yang et al   | 2018 | China   | Colorectal cancer | Tissue      | qRT-PCR     | 40         | Gender, age, tumor differentiation, stage, and lymph node metastasis | 6   |

GIST = gastrointestinal stromal tumor, NOS = the scores of Newcastle–Ottawa quality assessment scale, qRT-PCR = quantitative real-time polymerase chain reaction, SACC = salivary adenoid cystic carcinoma.
Subsequently, for tissue samples associated studies, subgroup analysis of OS was conducted by different statistic method, and better OS for patients with high miR-125a-5p expression remained statistically significant irrespective if the study used multivariate analysis (HR = 0.359, 95% CI: 0.240–0.539, \( P < .001 \)) or survival curve (HR = 0.539, 95% CI: 0.414–0.701, \( P < .001 \)). However, as for serum sample, the association between higher miR-125a-5p expression and better OS was not significant (HR = 0.574, 95% CI: 0.320–1.03, \( P = .063 \)). Additionally, statistical significance between high miR-125a-5p expression and favorable DFS was achieved based on tissue samples (HR = 0.343, 95% CI: 0.237–0.496, \( P < .001 \)). Furthermore, we conducted subgroup meta-analysis based on lung cancer and gastric cancer, and favorable OS was also found in lung cancer (HR = 0.343, 95% CI: 0.228–0.517, \( P < .001 \)) and gastric cancer (HR = 0.341, 95% CI: 0.160–0.725, \( P = .005 \)) patients with high miR-125a-5p expression (Table 3, Fig. 3).

### 3.3. High miR-125a-5p expression indicated favorable clinicopathologic parameters

The correlations between miR-125a-5p and clinicopathologic features including gender, age, tumor differentiation, stage, lymph node metastasis, and distant metastasis were analyzed based on pan-cancer/lung cancer/gastric cancer. High miR-125a-5p expression was only correlated with early stage (OR = 0.413, 95% CI: 0.228–0.749, \( P = .004 \)) and negative lymph node metastasis (OR = 0.262, 95% CI: 0.073–0.941, \( P = .04 \)) in gastric cancer, and was linked with better tumor differentiation in pan-cancer (OR = 1.623, 95% CI: 1.064–2.476, \( P = .025 \)) and lung cancer (OR = 2.371, 95% CI: 1.358–4.141, \( P = .002 \)). However, no significant association was detected in other clinicopathologic features (Table 3, Fig. 4).

### 4. Discussion

This was the 1st meta-analysis estimating the prognostic and clinicopathologic value of miR-125a-5p in human cancers. We found that high miR-125a-5p expression was related to significantly better prognosis and clinicopathologic parameters. The overexpression of miR-125a-5p in cancer tissue predicted better OS and DFS for patient, and also associated with less aggressive tumor biology, including better tumor differentiation and early stage and negative lymph node metastasis. However, based on the serum samples from cancer patients, the association between overexpression of miR-125a-5p and better OS was not statistically significant.

The expression of miRNA can be measured using various sources, including tissue, blood, and other bodily fluids, and the sampling and extraction methods had a significant effect on the results obtained. Although miRNAs are very stable in blood because they bind with Argonaute proteins, the miRNA levels in blood samples are minuscule and do not contain pure tumor cells. Our study did not reveal a prognostic value for serum-based miR-125a-5p sampling, and current studies also did not support blood-based sampling to investigate circulating miRNAs. Evidence suggested different miRNA concentrations in serum and plasma, mainly influenced by miRNAs generated from platelets, indicating that the coagulation process affects the detection of miRNAs in the blood. However, only 490 serum samples from 3 studies were included in our meta-analysis; thus, larger sample sizes are needed to verify our result.

A recent study found that miR-125a-5p inhibits the proliferation, migration, and invasion of colorectal cancer cell lines, and suppresses growth and metastasis in vivo. Additionally, miR-125a-5p suppresses the tube formation ability of human umbilical vein endothelial cells and VEGFA, a target of miR-125a-5p, may reverse this suppression caused by miR-125a-5p upregulation. In bladder cancer, high expression of miR-125a-5p was a cell cycle inhibitor; miR-125a-5p inhibited proliferation, migration, and invasion of cancer cells while inducing apoptosis. The upregulation of miR-125a-5p reversed the epithelial–mesenchymal transition, and FUT4, which targets the miRNA of miR-125a-5p, reversed the effects of miR-125a-5p on bladder cancer progression. Furthermore, miR-125a-5p inhibited cell proliferation and migration through NAIF1 in prostate cancer and suppressed cervical cancer cell proliferation and migration by targeting ABL. Although our study revealed that miR-125a-5p overexpression predicted better prognosis and tumor differentiation for cancer patients, there were also several limitations in our study. Firstly, we could only analyze data from literature rather than original data, this impeded us to estimate all the data by consistent method and inevitably led to significant heterogeneity.
### Table 3
Summarized HRs and ORs in this meta-analysis.

| Group                                      | Studies | Sample size | HR/OR (95% CI)                  | P-value | I² (%) | P-value | Model         |
|--------------------------------------------|---------|-------------|---------------------------------|---------|--------|---------|---------------|
| OS (pan-cancer, tissue)                    | 10      | 1383        | 0.459 (0.369–0.57)              | <.001   |        |         | Random effect model |
| OS (pan-cancer, tissue, multivariate)      | 6       | 972         | 0.359 (0.240–0.539)             | <.001   |        |         | Random effect model |
| OS (pan-cancer, tissue, survival curve)    | 4       | 411         | 0.539 (0.414–0.701)             | <.001   |        |         | Random effect model |
| OS (pan-cancer, serum)                     | 3       | 490         | 0.574 (0.320–1.03)              | .063    |        | .322    | Random effect model |
| DFS (pan-cancer, tissue)                   | 2       | 670         | 0.343 (0.237–0.496)             | <.001   |        |         | Random effect model |
| OS (lung cancer, tissue)                   | 3       | 559         | 0.343 (0.228–0.517)             | <.001   |        | .456    | Random effect model |
| OS (gastric cancer, tissue)                | 3       | 455         | 0.341 (0.160–0.725)             | .005    |        | .125    | Random effect model |
| Gender (pan-cancer/lung cancer/gastric cancer) | 11/3/4 | 1437/506/506 | 1.116 (0.884–1.409)/0.770 (0.302–1.967)/1.295 (0.888–1.932) | .354/1.585/.006 | 65.1%/0%/0% | .413/0.057/6 | Fixed effect model/Random effect model/Fixed effect model |
| Age (pan-cancer/lung cancer/gastric cancer) | 10/3/3 | 1360/506/419 | 0.782 (0.608–1.005)/0.758 (0.510–1.218)/0.807 (0.501–1.301) | .055/1.722/.379 | 0%/0%/0% | .987/1.419/1.955 | Fixed effect model/Fixed effect model/Fixed effect model |
| Stage (pan-cancer/lung cancer/gastric cancer) | 9/3/3 | 984/506/220 | 0.647 (0.352–1.19)/0.866 (0.224–4.62/8.35)/0.004 (3.347–0.413) | 0.282–0.74 (0.228–0.749) | 71.3%/85.1%/0% | <.001/0.01/3.06 | Random effect model/Random effect model/Fixed effect model |
| Tumor differentiation (pan-cancer/lung cancer/gastric cancer) | 11/3/4 | 1437/506/506 | 1.623 (1.004–2.476)/2.371 (1.358–4.141)/0.904 (0.438–1.868) | .025/0.022/0.785 | 56.2%/59.1%/0% | .011/7.39/0.062 | Random effect model/Fixed effect model/Fixed effect model |
| Lymph node metastasis (pan-cancer/lung cancer/gastric cancer) | 10/3/4 | 1158/506/506 | 0.473 (0.219–1.019)/0.975 (0.242–3.955)/0.262 (0.073–0.941) | .056/0.976/4 | 81.4%/87%/82.9% | <.001/0.01/0.01 | Random effect model/Fixed effect model/Fixed effect model |
| Distant metastasis (pan-cancer)             | 4       | 571         | 0.770 (0.183–3.233)             | .721    |        | .001    | Random effect model |

DFS = disease-free survival, HR = hazard ratio, OR = odds ratio, OS = overall survival.
Secondly, due to no available original data, the confounding factors such as treatment, race, and age cannot be evaluated and might also contribute to heterogeneity. Additionally, all studies were carried out in Asia with the exception of one study was conducted in Sweden; more studies should be carried out in other regions. Finally, significant publication bias was detected in the studies for OS which based on tissue sample.

In conclusion, miR-125a-5p is a tumor suppressor with prognostic and clinicopathologic values for human cancer, and miR-125a-5p overexpression predicted favorable prognosis, early stage, negative lymph node metastasis, and better tumor differentiation. More research should be conducted to test these results.

Acknowledgments
The authors thank Editage English service for their language editing.

Author contributions
Conceptualization: Haidong Ye, Lina Mei, Zhouxiang Lu.
Data curation: Haidong Ye, Wei Zhu.
Formal analysis: Zhouxiang Lu.
Methodology: Wei Zhu.
Software: Wei Zhu, Zhouxiang Lu.
Validation: Wei Zhu, Lina Mei.
Writing – original draft: Haidong Ye, Zhouxiang Lu.
Writing – review & editing: Wei Zhu, Lina Mei, Zhouxiang Lu.
References

[1] Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10:126–39.
[2] Xu Y, Huang Z, Liu Y. Reduced miR-125a-5p expression is associated with gastric carcinogenesis through the targeting of EZF3. Mol Med Rep 2014;10:2601–8.
[3] Jiang L, Huang Q, Zhang S, et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 2010;10:318.
[4] Di Leva G, Croce CM. miRNA profiling of cancer. Curr Opin Genet Dev 2013;23:3–11.
[5] Cai M, Chen Q, Shen J, et al. Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer 2018;22:4721–31.
[6] Cao Y, Tan S, Tu Y, et al. MicroRNA-125a-5p inhibits invasion and metastasis of gastric cancer cells by targeting BRMS1 expression. Oncol Lett 2018;15:5119–30.
[7] Liu H, Ma Y, Liu C, et al. Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression. Open Biol 2018;8:
[8] Hsueh TH, Hsu CY, Tsai CF, et al. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. Oncotarget 2015;6:494–509.
[9] Sun L, Zhang B, Liu Y, et al. MiR125a-5p acting as a novel Gab2 suppressor inhibits invasion of glioma. Mol Carcinog 2016;55: 40–51.
[10] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
[11] Wang Y, Li J, Tong L, et al. The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: a meta-analysis. Jpn J Clin Oncol 2013;43:813–20.
[12] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
[13] Riley RD, Elia EG, Malin G, et al. Multivariate meta-analysis of prognostic factor studies with multiple cut-points and/or methods of measurement. Stat Med 2015;34:2481–96.
[14] Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011;17:2725–33.
[15] Zhang YK, Zhu WY, He JY, et al. miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes. J Cancer Res Clin Oncol 2012;138:1641–50.
[16] Akcaayakaya P, Caramuta S, Ahlen J, et al. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014;111:2091–102.
[17] Zhu WY, Luo B, An JY, et al. Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer. Cancer Invest 2014;32:394–401.
[18] Zhang J, Zhou Z, Xu Z, et al. Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression. Mol Med Rep 2015;12:1584–90.
[19] Zhang Y, Xue C, Zhu X, et al. Suppression of microRNA-125a-5p upregulates the TAZ-EGFR signaling pathway and promotes retinoblastoma proliferation. Cell Signal 2016;28:850–60.
[20] Liang Y, Ye J, Jiao J, et al. Down-regulation of miR-125a-5p is associated with salivary adenoid cystic carcinoma progression via targeting p38/JNK/ERK signal pathway. Ann J Transl Res 2017;9:1101–13.

Figure 4. The forest plots for the associations between miR-125a-5p and stage (A), lymph node metastasis (B) in gastric cancer, tumor differentiation in pan-cancer (C), and lung cancer (D).
[21] Yang X, Qiu J, Kang H, et al. miR-125a-5p suppresses colorectal cancer progression by targeting VEGFA. Cancer Manag Res 2018;10:5839–53.
[22] Zhang P, Liu Y, Fu C, et al. Knockdown of long non-coding RNA PCAT1 in glioma stem cells promotes radiation sensitivity 2019;52:114–22.
[23] Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012;13:358–69.
[24] Meister G. Argonaute proteins: functional insights and emerging roles. Nat Rev Genet 2013;14:447–59.
[25] Halkova T, Cuperkova R, Minarik M. MicroRNAs in pancreatic cancer: involvement in carcinogenesis and potential use for diagnosis and prognosis 2015;2015:892903.
[26] Negoi I, Hostiuc S, Sartelli M, et al. MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer - a systematic review and meta-analysis. Am J Surg 2017;214:515–24.

[27] Butz H, Patocs A. Technical aspects related to the analysis of circulating microRNAs. Exp Suppl 2015;106:55–71.
[28] Zhang Y, Zhang D, Lv J, et al. MiR-125a-5p suppresses bladder cancer progression through targeting FUT4. Biomed Pharmacother 2018;108:1039–47.
[29] Fu Y, Cao F. MicroRNA-125a-5p regulates cancer cell proliferation and migration through NAIF1 in prostate carcinoma. Onco Targets Ther 2015;8:3827–35.
[30] Qin X, Wan Y, Wang S, et al. MicroRNA-125a-5p modulates human cervical carcinoma proliferation and migration by targeting ABL2. Drug Des Devel Ther 2016;10:71–9.
[31] Huang Y, Tang J, Tam WW, et al. Comparing the overall result and interaction in aggregate data meta-analysis and individual patient data meta-analysis. Medicine (Baltimore) 2016;95:e3312.